Clinical Trials · NCT01301092
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 30
- Start date
- Feb 2011
- Locations
- 1 site, United States
- Primary endpoint
- Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)